Table 2.
Clinical characteristics of the JHS and FHS study cohorts
| JHS | FHS | |||
| Total sample (n = 1,928) | Subset with eGFR slope (n = 1,371) | Total sample (n = 1,621) | Subset with eGFR slope (n = 1,332) | |
| Age, y | 56 ± 13 | 55 ± 12 | 55 ± 10 | 54 ± 10 |
| Women, % | 61% | 61% | 53% | 54% |
| Race/ethnicity | 100% AA | 100% AA | 100% CW | 100% CW |
| eGFR, mL/min/1.73 m2 | 93 ± 23 | 95 ± 21 | 89 ± 20 | 90 ± 20 |
| Albuminuria, % | 14%* | 11%† | 24%‡ | 23%§ |
| BMI, kg/m2 | 32 ± 7.3 | 32 ± 7.2 | 27.5 ± 5.0 | 27.5 ± 5.0 |
| Diabetes, % | 23% | 20% | 8% | 6% |
| Hypertension, % | 57% | 54% | 35% | 33% |
| Current smoker, % | 13% | 11% | 19% | 18% |
| High risk APOL1 genotype, % | 14% | 13% | — | — |
| eGFR decline, mL/min/1.73 m2 per y | −1.2 ± 1.9 | −1.0 ± 2.7 | ||
Values are mean ± SD or percentage. AA, African-American; CW, Caucasian White. Albuminuria in JHS defined as microalbumin/creatinine ratio ≥30 mg/g. Albuminuria in FHS defined as greater than or equal to trace on urine dipstick.
*
n = 1,033.
†
n = 673.
‡
n = 1,556.
§
n = 1,284.